Hagop Kantarjian

Hagop Kantarjian is a high senior professor at The University of Texas MD Anderson Cancer Center, where he specializes in hematology and oncology. His research focuses on hematological malignancies, particularly chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and myeloid neoplasia, integrating pharmacology, immunology, and cancer research. His recent publications include the 2025 European LeukemiaNet recommendations for CML management and updates on adult ALL diagnosis and therapy. He has also explored reduced venetoclax exposure in AML and TP53-mutant variant allele frequency in MDS/AML transplantation. His work on immunogenomic determinants in renal cell carcinoma highlights his collaborative, international impact in precision oncology.